Biovance Capital

Biovance Capital is a venture capital firm based in Lisbon, Portugal, specializing in early-stage investments within the biopharma and biotech sectors across Europe. The firm focuses on disruptive companies developing transformative therapies across various modalities and therapeutic areas. They primarily engage in Seed and Series A funding rounds, often co-investing with additional partners to enhance value and mitigate risk. Biovance Capital's investment strategy targets companies with robust preclinical models, patented or patentable assets, and a clear path to market in large target markets with favorable regulatory and reimbursement landscapes.

Biovance Capital Partners was established in July 2023, emerging from the team of Bionova Capital. The firm was founded with the mission to empower visionary scientists and groundbreaking innovations in medicine, particularly by building a dedicated biotech fund in Portugal. Ricardo Perdigão Henriques, Managing Partner, highlighted the significance of Biovance Capital Fund I as a milestone for Portugal's biomedical ecosystem, aiming to support innovative biotech companies across Europe. The firm's inception was publicly announced with support from key entities like the European Investment Fund (EIF) and Banco Português de Fomento (BPF).

Biovance Capital manages Fund I, a biotech-focused fund with a target size of €60 million, backed by the European Investment Fund, the European Commission, and other public and private investors. Notable investments include leading a Series A round in Mondego Bio alongside OrbiMed and Torrey Pines, and co-leading an oversubscribed €17 million seed round for Laigo Bio with a €4 million investment.

The Biovance Capital team brings decades of experience and a robust network within the biopharma and biotech industries, offering deep scientific and financial insights. The multidisciplinary team comprises individuals with PhDs, MDs, and accomplished inventor backgrounds, educated at prestigious institutions such as Harvard, MIT, and Imperial College. Key team members include Ricardo Perdigão Henriques (Managing Partner), João Incio (General Partner), and André Albergaria (Principal). This blend of scientific expertise and business acumen enables the firm to work closely with entrepreneurs to build leading companies.